Involvement of potential pathways in malignant transformation from oral leukoplakia to oral squamous cell carcinoma revealed by proteomic analysis.
BACKGROUND
Oral squamous cell carcinoma (OSCC) is one of the most common forms of cancer associated with the presence of precancerous oral leukoplakia. Given the poor prognosis associated with oral leukoplakia, and the difficulties in distinguishing it from cancer lesions, there is an urgent need to elucidate the molecular determinants and critical signal pathways underlying the malignant transformation of precancerous to cancerous tissue, and thus to identify novel diagnostic and therapeutic target.


RESULTS
We have utilized two dimensional electrophoresis (2-DE) followed by ESI-Q-TOF-LC-MS/MS to identify proteins differentially expressed in six pairs of oral leukoplakia tissues with dysplasia and oral squamous cancer tissues, each pair was collected from a single patient. Approximately 85 differentially and constantly expressed proteins (> two-fold change, P < 0.05) were identified, including 52 up-regulated and 33 down-regulated. Gene ontological methods were employed to identify the biological processes that were over-represented in this carcinogenic stage. Biological networks were also constructed to reveal the potential links between those protein candidates. Among them, three homologs of proteosome activator PA28 a, b and g were shown to have up-regulated mRNA levels in OSCC cells relative to oral keratinocytes.


CONCLUSIONS
Varying levels of differentially expressed proteins were possibly involved in the malignant transformation of oral leukoplakia. Their expression levels, bioprocess, and interaction networks were analyzed using a bioinformatics approach. This study shows that the three homologs of PA28 may play an important role in malignant transformation and is an example of a systematic biology study, in which functional proteomics were constructed to help to elucidate mechanistic aspects and potential involvement of proteins. Our results provide new insights into the pathogenesis of oral cancer. These differentially expressed proteins may have utility as useful candidate markers of OSCC.
Wang
Zhi
Z
State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, 610041, Sichuan, PR China. wangzhi0506@126.com
Feng
Xiaodong
X
Liu
Xinyu
X
Jiang
Lu
L
Zeng
Xin
X
Ji
Ning
N
Li
Jing
J
Li
Longjiang
L
Chen
Qianming
Q
D014408:Biomarkers, Tumor / Q000235:genetics; D002294:Carcinoma, Squamous Cell / Q000235:genetics* / Q000473:pathology; D045744:Cell Line, Tumor; D002851:Chromatography, High Pressure Liquid; D015180:Electrophoresis, Gel, Two-Dimensional; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007972:Leukoplakia, Oral / Q000235:genetics* / Q000473:pathology; D009062:Mouth Neoplasms / Q000235:genetics* / Q000473:pathology; D009124:Muscle Proteins / Q000235:genetics; D046988:Proteasome Endopeptidase Complex / Q000235:genetics; D040901:Proteomics / Q000379:methods*; D053719:Tandem Mass Spectrometry
D014408:Biomarkers, Tumor; D009124:Muscle Proteins; C085047:PSME1 protein, human; D046988:Proteasome Endopeptidase Complex
Am J Surg Pathol. 2008 Feb;32(2):188-96
18223320
Br J Cancer. 2008 Jan 29;98(2):426-33
18071363
Electrophoresis. 1999 Dec;20(18):3551-67
10612281
Exp Cell Res. 2006 Jan 15;312(2):184-97
16297907
Curr Top Microbiol Immunol. 2002;268:73-89
12083009
J Cancer Res Clin Oncol. 2007 Apr;133(4):253-61
17136347
Oral Oncol. 2003 Sep;39(6):589-96
12798402
Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6872-9
16203777
Curr Cancer Drug Targets. 2008 Jun;8(4):243-52
18537548
Proteomics. 2004 Jan;4(1):271-8
14730689
Cancer Lett. 2004 Jun 8;209(1):111-8
15145526
J Proteome Res. 2006 Dec;5(12):3429-32
17137344
Mol Cell Proteomics. 2008 Sep;7(9):1639-50
18458027
J Otolaryngol. 2006 Jun;35(3):157-66
16929991
J Urol. 1996 Jun;155(6):2105-12
8618345
J Proteome Res. 2007 Jun;6(6):2143-51
17451265
J Invest Dermatol. 1992 Sep;99(3):299-305
1512466
Int J Oncol. 2005 Jul;27(1):59-67
15942644
Clin Cancer Res. 2000 May;6(5):1702-10
10815888
Bioessays. 2000 May;22(5):442-51
10797484
Exp Cell Res. 1989 May;182(1):284-9
2541006
Laryngoscope. 2005 Apr;115(4):690-8
15805883
Int J Oncol. 2006 Apr;28(4):873-81
16525636
Histopathology. 2005 Mar;46(3):256-69
15720411
Nat Rev Immunol. 2003 Dec;3(12):952-61
14647477
Clin Cancer Res. 2003 Jul;9(7):2627-31
12855640
Oral Oncol. 2009 Aug;45(8):731-6
19147391
J Proteome Res. 2008 Sep;7(9):3818-29
18700792
Hum Pathol. 2004 Nov;35(11):1385-91
15668896
J Immunol. 2004 Mar 15;172(6):3948-54
15004203
Oncogene. 2008 Jun 5;27(25):3527-38
18223693
Electrophoresis. 1999 Dec;20(18):3638-46
10612291
Int J Mol Med. 2006 Feb;17(2):253-60
16391823
Clin Cancer Res. 2008 Oct 1;14(19):6246-52
18829504
J Biol Chem. 2006 Dec 15;281(50):38905-17
17030513
Am J Pathol. 2004 Jan;164(1):73-9
14695321
Mol Cell Proteomics. 2008 Mar;7(3):486-98
18045803
Cancer Res. 2006 Feb 1;66(3):1255-60
16452175
Nat Immunol. 2004 Jul;5(7):685-92
15224094